UC-CARE Overview
UC-CARE has developed a patented diagnostic and treatment system designed to improve procedures for prostate diseases. The system aims to solve the problem of blind biopsies and to provide an improved system for focal treatment. Navigo is a device that allows physicians to image, plan, place, and record prostate biopsy samples in high-resolution 3D, allowing them to more confidently sample precise areas of the prostate and record biopsy locations for future reference. Navigo Viewer is a CD given to patients upon completion of the procedure. It enables patients and the referring physician to view the procedure summary and keep a record for future follow-ups. SmartBx is a biopsy core preservation and management system that is designed to seamlessly integrate into the TRUS biopsy procedure and contribute to a high cancer-detection rate and improved cancer management, especially for active surveillance processes. Navigo Fusion Studio is a software solution for fusion planning. Its automated algorithms allow radiologists and urologists to quickly prepare images to be processed by Navigo. Cases are automatically sent to the Navigo workstation, streamlining the process from planning to procedure.
Cumulative Funding Raised Over Time ($)
$560KFeb 2007
$1.6MMar 2019
Latest News
growth-positive
Israeli company gets $1M to expand here - Jewish Press of Tampa
Israeli medical device company UC-Care has received a $1 million investment from Florida Funders to support its operations in Florida. UC-Care offers medical devices for prostate cancer diagnosis and treatment, and its products have been approved by the FDA. The investment was facilitated through a joint venture between UC-Care and Florida Funders, a crowd funding and venture capital platform. The Florida-Israel Business Accelerator (FIBA) played a role in introducing UC-Care to the Florida market and connecting them with potential customers. FIBA has brought a total of 27 Israeli companies to Tampa since 2017. UC-Cares decision to establish an office and storage facility in Oldsmar was driven by positive responses from potential clients and healthcare professionals in Florida.
Investment
growth-positive
AXELLA and UC-CARE Announce the Navigo™ and SmartBx™ Systems New cutting edge vision for prostate MRI fusion biopsy
AXELLAs Navigo™, a revolutionary device for prostate biopsies, has been purchased by WESTMED Medical Group and Rochester General Hospital. The Navigo™ fuses MRI images with live ultrasound images to provide accurate and advanced prostate biopsy procedures. It allows for 3D modeling of the prostate and precise localization of cancer. The SmartBx™ Prostate Biopsy System, which integrates with the Navigo™, contributes to higher cancer detection rates and management. The system preserves and manages biopsy cores, ensuring accurate orientation and enhanced cancer diagnosis. The Path-lab findings are integrated with the Navigo™ system to provide high accuracy in prostate cancer management. The article highlights the advantages of the Navigo™ and SmartBx™ in battling prostate cancer.
Customers
growth-positive
Meytav incubator plans to raise $37m in 2007
Meytav Technological Enterprises Innovation Center Ltd. plans to raise $37 million in private and public money for its portfolio companies. The company has a detailed plan to raise money for each company, including graduate companies like Collplant, Endogun Medical Systems, Elutex, Helix Medical Systems, and UC Care. They also mentioned new companies that plan to raise capital. Meytavs fundraising plans are unrelated to the capital raising plans of its parent company, Biomedix Incubator Ltd., which is also investing in Meytavs portfolio companies.
Investment
growth-positive
Prostate treatment revolution
UC-Care Medical Systems Ltd. has developed a mechanical device for the treatment of benign prostatic hyperplasia (BPH) that does not harm the urethra. The device involves a rigid catheter with a viewfinder that allows for precise treatment of tissue near the urethra without damaging it. The company has raised $560,000 to date and is conducting clinical trials in Israel. They expect the regulatory procedures with the US Food and Drug Administration (FDA) to be straightforward and anticipate completing the trials in a few months. The device is aimed at BPH patients who require more than medication but fear invasive treatments. The company expects doctors to embrace the product due to its simplicity and potential profitability.
CustomersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $1.56M |
| Last funding | $1M |
| Stage | Mature |
| Rounds | 2 |
| Investors | 2 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | www.uc-care.com |
Locations
HaTamar 2, Yokne'am Illit, Israel
Tampa, Florida, USA
Photos & Videos
2 item(s)
UC-CARE Business
Business models
B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesDiagnostics DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersPatientsCore Technology
Platforms & InterfacesSoftwareSimulation & ImagingTags (15)
doctorsimagingbiopsyoncologycancermedical-technologiesdiagnosticsmedical-devices3d-technologyhospitalspatientsurologysoftware-developmentoptronicstreatmentsGeographic Markets
GlobalUC-CARE Financials
$1.56M
Total funding
Undisclosed
Capital raised
$1M
Last funding
Mature
Funding stage
2
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$560KFeb 2007
$1.6MMar 2019
Private Equity Funding
Undisclosed Round
Mar 2019
$1M
Florida Funders
Seed
Feb 2007
$560K
Meytav Technological Incubator
UC-CARE Lifecycle
Cumulative Funding Raised Over Time
$560KFeb 2007
$1.6MMar 2019
All Events
Undisclosed Round
Mar 2019
$1M
Florida Funders
Seed
Feb 2007
$560K
Meytav Technological Incubator
UC-CARE News
4 articles
growth-positive
Israeli company gets $1M to expand here - Jewish Press of Tampa
Israeli medical device company UC-Care has received a $1 million investment from Florida Funders to support its operations in Florida. UC-Care offers medical devices for prostate cancer diagnosis and treatment, and its products have been approved by the FDA. The investment was facilitated through a joint venture between UC-Care and Florida Funders, a crowd funding and venture capital platform. The Florida-Israel Business Accelerator (FIBA) played a role in introducing UC-Care to the Florida market and connecting them with potential customers. FIBA has brought a total of 27 Israeli companies to Tampa since 2017. UC-Cares decision to establish an office and storage facility in Oldsmar was driven by positive responses from potential clients and healthcare professionals in Florida.
Investment
growth-positive
AXELLA and UC-CARE Announce the Navigo™ and SmartBx™ Systems New cutting edge vision for prostate MRI fusion biopsy
AXELLAs Navigo™, a revolutionary device for prostate biopsies, has been purchased by WESTMED Medical Group and Rochester General Hospital. The Navigo™ fuses MRI images with live ultrasound images to provide accurate and advanced prostate biopsy procedures. It allows for 3D modeling of the prostate and precise localization of cancer. The SmartBx™ Prostate Biopsy System, which integrates with the Navigo™, contributes to higher cancer detection rates and management. The system preserves and manages biopsy cores, ensuring accurate orientation and enhanced cancer diagnosis. The Path-lab findings are integrated with the Navigo™ system to provide high accuracy in prostate cancer management. The article highlights the advantages of the Navigo™ and SmartBx™ in battling prostate cancer.
Customers
growth-positive
Meytav incubator plans to raise $37m in 2007
Meytav Technological Enterprises Innovation Center Ltd. plans to raise $37 million in private and public money for its portfolio companies. The company has a detailed plan to raise money for each company, including graduate companies like Collplant, Endogun Medical Systems, Elutex, Helix Medical Systems, and UC Care. They also mentioned new companies that plan to raise capital. Meytavs fundraising plans are unrelated to the capital raising plans of its parent company, Biomedix Incubator Ltd., which is also investing in Meytavs portfolio companies.
Investment
growth-positive
Prostate treatment revolution
UC-Care Medical Systems Ltd. has developed a mechanical device for the treatment of benign prostatic hyperplasia (BPH) that does not harm the urethra. The device involves a rigid catheter with a viewfinder that allows for precise treatment of tissue near the urethra without damaging it. The company has raised $560,000 to date and is conducting clinical trials in Israel. They expect the regulatory procedures with the US Food and Drug Administration (FDA) to be straightforward and anticipate completing the trials in a few months. The device is aimed at BPH patients who require more than medication but fear invasive treatments. The company expects doctors to embrace the product due to its simplicity and potential profitability.
CustomersInvestment
UC-CARE Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 17 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
UC-CARE Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 91/100 |
| Missing | markets, not claimed |
| BI Verification | Sharon Shapira |
| Registrar ID | 513550871 |
| Phone | +97249097427 |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-01-18T00:00:00.000Z |
| Created | 2014-11-24T00:00:00.000Z |